Adipose-Derived Mesenchymal Stromal Cells in Regenerative Medicine: State of Play, Current Clinical Trials, and Future Prospects
| Autor: | Jérôme Laloze, Alexis Desmoulière, Loïc Fiévet |
|---|---|
| Přispěvatelé: | Maintenance Myélinique et Neuropathies Périphériques (MMNP), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de Chirurgie maxillo-faciale, réparatrice et stomatologie [CHU Limoges], CHU Limoges, STROMALab, Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Etablissement Français du Sang-Institut National de la Santé et de la Recherche Médicale (INSERM), Nizou, Angélique, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement Français du Sang-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Skin innervation [SDV]Life Sciences [q-bio] Cell Plasticity Pain Wound healing Mesenchymal Stem Cell Transplantation Critical Care and Intensive Care Medicine Bioinformatics Regenerative medicine law.invention Cell therapy Cicatrix 030207 dermatology & venereal diseases 03 medical and health sciences Advanced therapy medicinal product 0302 clinical medicine Randomized controlled trial Comprehensive Invited Review Fibrosis law medicine Animals Humans Clinical Trials as Topic Tissue Engineering business.industry Mesenchymal stem cell Consolidated Standards of Reporting Trials Mesenchymal Stem Cells medicine.disease 3. Good health [SDV] Life Sciences [q-bio] Clinical trial 030104 developmental biology Quality of Life Emergency Medicine Adipose-derived mesenchymal stromal cell Chronic Pain Burns business |
| Zdroj: | Advances in Wound Care Advances in Wound Care, 2021, 10 (1), pp.24-48. ⟨10.1089/wound.2020.1175⟩ Adv Wound Care (New Rochelle) |
| ISSN: | 2162-1934 2162-1918 |
| DOI: | 10.1089/wound.2020.1175 |
| Popis: | International audience; Significance: Wound healing is a complex process involving pain and inflammation, where innervation plays a central role. Managing wound healing and pain remains an important issue, especially in pathologies such as excessive scarring (often leading to fibrosis) or deficient healing, leading to chronic wounds. Recent Advances: Advances in therapies using mesenchymal stromal cells offer new insights for treating indications that previously lacked options. Adipose-derived mesenchymal stromal cells (AD-MSCs) are now being used to a much greater extent in clinical trials for regenerative medicine. However, to be really valid, these randomized trials must imperatively follow strict guidelines such as consolidated standards of reporting trials (CONSORT) statement. Indeed, AD-MSCs, because of their paracrine activities and multipotency, have potential to cure degenerative and/or inflammatory diseases. Combined with their relatively easy access (from adipose tissue) and proliferation capacity, AD-MSCs represent an excellent candidate for allogeneic treatments. Critical Issues: The success of AD-MSC therapy may depend on the robustness of the biological functions of AD-MSCs, which requires controlling source heterogeneity and production processes, and development of biomarkers that predict desired responses. Several studies have investigated the effect of AD-MSCs on innervation, wound repair, or pain management separately, but systematic evaluation of how those effects could be combined is lacking. Future Directions: Future studies that explore how AD-MSC therapy can be used to treat difficult-to-heal wounds, underlining the need to thoroughly characterize the cells used, and standardization of preparation processes are needed. Finally, how this a priori easy-to-use cell therapy treatment fits into clinical management of pain, improvement of tissue healing, and patient quality of life, all need to be explored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|